NMPA approves toripalimab combined with bevacizumab for 1L treatment of HCC in China

Dr. Jianjun Zou, General Manager and CEO of Junshi Biosciences, said: “Based on the ‘Ten Perfections’, Toripalimab continues to make breakthroughs and has been officially approved for its 11th indication, which makes us very excited! As the country with the heaviest burden of liver cancer in the world, liver cancer patients in China have long faced the dilemma of limited treatment options. Junshi Biosciences has long focused on the clinical needs in the field of liver cancer treatment worldwide, and has arranged clinical studies using multi-combination strategies for different disease course populations, aiming to provide liver cancer patients with more accurate and richer treatment options. We will continue to be committed to drug innovation in this field and inject more powerful ‘Chinese wisdom’ into the fight against liver cancer.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib